Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chewed vs Integral Ticagrelor in PCI
NCT03708588Phase 4Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in coronary artery disease (CAD) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Concentration of Pharmacodynamics (Platelet Reactivity Units) at 1 hour. Started Sep 2018; status: completed.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03708588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708588.